Cut-and-paste patent report withdrawn

India rejects Microsoft's Office Open XML

A treaty to block cheaper drugs

Developed countries to use a geographical advantage to stop generics

In praise of open-source innovation

India slams mania for patents and says open-source models work better to spur innovation

Annoying the US, our way

Despite close cooperation with American enforcement officials, US unhappy with India’s report card

Life industry goldrush

Trade in bio-industrial products is on in full swing, conjuring up visions of El dorado. But whether the Indian industry can embark on this …

Dispensing with dear drugs

New US law to clear the decks for generic drugs (Read full article)

Gene patent verdict is as good as it gets

The US Supreme Court’s verdict in the Myriad case keeps everyone happy

Back where it belongs

India emerges victorious from a legal wrangle with the US over the patenting of neem

Traditional Indian medicinal practices now safe

Chirala saree weavers losing out to computer-aided designs

The scent that sells

Big blue trips up Twitter

IBM’s claim of patent violation by Twitter reflects the madness in software litigation in the US

Looming threat of a secretive trade pact

Trans-Pacific Partnership agreement will extend restrictive intellectual property laws globally

Will the boom last?

Fifteen years after it rose and went limp, the biotech sector, globally, as well as in India has seen a bull run of sorts. In January this year, …

TRIPPED

On December 26, 2004, the Union government of India issued the Patents (Amendments) Ordinance, which will change the way the country does …

US piles on the pressure

Patent law, domestic content rules in solar and ICT policy come under attack

In Court

In Short

Fight over Novartis's patent to intensify

Sri Lanka bans export of high-value medicinal plant

Madras HC dismisses Novartis' petition

Ranbaxy fights Pfizer on generic drugs but wants strong home law on patents

Nagaur breaks free of pharma stranglehold

Rajasthan, Tamil Nadu make quality drugs affordable

No patent linkage

Bayer’s attempt to pre-empt Cipla’s cancer drug fails